Cantor Fitzgerald Predicts TG Therapeutics FY2025 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of TG Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biopharmaceutical company will post earnings per share of $1.08 for the year, up from their previous estimate of $0.72. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share.

TGTX has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday. JPMorgan Chase & Co. upped their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Finally, StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Trading Down 1.4 %

Shares of TGTX opened at $35.11 on Thursday. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm has a fifty day simple moving average of $30.86 and a two-hundred day simple moving average of $28.33. The stock has a market capitalization of $5.47 billion, a P/E ratio of -351.06 and a beta of 2.30. TG Therapeutics has a twelve month low of $12.93 and a twelve month high of $36.94.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

Insider Activity

In other news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

A number of large investors have recently bought and sold shares of TGTX. Vermillion Wealth Management Inc. purchased a new stake in TG Therapeutics during the 4th quarter valued at about $30,000. Quadrant Capital Group LLC grew its holdings in shares of TG Therapeutics by 137.1% in the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 975 shares in the last quarter. Blue Trust Inc. boosted its holdings in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 371 shares during the period. Smartleaf Asset Management LLC grew its position in shares of TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 1,594 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its stake in shares of TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 1,737 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.